Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The inflammatory response and epoetin sensitivity.

Iain C Macdougall1, Angela Cooper

  • 1Department of Renal Medicine, King's College Hospital, London, UK. icm-kru@globalnet.co.uk

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|January 29, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Supervised and Self-Directed Technology-Based Dual-Task Exercise Training Program for Older Adults With a History of Falls: Mixed Methods Feasibility Study.

JMIR aging·2026
Same author

Cardiovascular Trials in Hemodialysis: Closing the Evidence Gap.

Journal of the American College of Cardiology·2026
Same author

Emergency management of anaphylaxis and the impact of the new UK advanced life support guidelines.

Clinical medicine (London, England)·2025
Same author

Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes.

European journal of heart failure·2025
Same author

Effects of Ferric Derisomaltose in Heart Failure with Iron Deficiency according to Renal Function in the IRONMAN Randomised Controlled Trial.

American journal of nephrology·2025
Same author

Recurrent event analyses in patients receiving maintenance dialysis and the effect of higher- versus lower-dose chronic intravenous iron therapy: A report focusing on heart failure events from the PIVOTAL trial.

European journal of heart failure·2025

Poor responsiveness to epoetin therapy in kidney disease patients may stem from heightened immune activation. This immune response, indicated by specific T-cell changes and increased inflammatory cytokines, is linked to poorer survival rates.

Area of Science:

  • Nephrology
  • Immunology
  • Hematology

Background:

  • Epoetin therapy exhibits variable patient responsiveness, with factors like iron deficiency, infection, and under-dialysis partially explaining resistance.
  • Uremia is a chronic inflammatory state, potentially impacting erythropoiesis through pro-inflammatory cytokines like IL-1, TNF-alpha, and IFN-gamma.
  • The precise mechanisms behind unexplained epoetin resistance remain unclear, prompting investigation into immune system involvement.

Purpose of the Study:

  • To investigate the hypothesis that enhanced immune activation and pro-inflammatory cytokine release contribute to epoetin resistance in patients.
  • To compare immune profiles, including T-cell phenotypes and cytokine generation, between 'good' and 'poor' responders to epoetin therapy.

Main Methods:

  • Flow cytometry was used to analyze T-cell phenotypes (CD4+, CD8+, CD28 expression).

Related Experiment Videos

  • Cytokine release (IL-10, IL-12, TNF-alpha) from peripheral blood mononuclear cells (PBMCs) was measured in patients undergoing epoetin therapy.
  • Patients were categorized as 'good' or 'poor' responders and followed for 24 months.

    • Main Results:

    • Poor responders demonstrated significantly reduced CD28 expression on CD4+ and CD8+ T cells.
    • Enhanced IL-10 generation from PBMCs, higher plasma IL-12 levels, and increased TNF-alpha release were observed in poor responders.
    • Poor responders exhibited a considerably lower 24-month survival rate (54%) compared to good responders (88%).

    Conclusions:

    • Enhanced immune activation, characterized by specific T-cell alterations and increased pro-inflammatory cytokine production, may underlie epoetin resistance.
    • This immune dysregulation is associated with significantly reduced patient survival.
    • Further research is needed to confirm the role of immune activation in epoetin resistance and its clinical implications.